Alkem Laboratories promoters sold a 1.5% stake in the company for ₹930 crore through a block deal, reducing their holding below 50%, according to thehindubusinessline.com. The transaction marks a significant change in promoter shareholding in the pharmaceutical firm, with the deal executed recently on the stock market.
The block deal was conducted on the stock exchange, where promoters offloaded shares worth ₹930 crore. This sale brought the promoter holding to under the 50% threshold, signaling a strategic move by the promoters to monetize part of their stake. The deal was reported during active market trading, with the Sensex and Nifty indices showing gains on the day.
This stake sale is notable in the context of promoter shareholding trends in Indian pharmaceutical companies, where maintaining control is often prioritized. Comparable transactions in the sector have seen promoters reducing holdings to raise capital or comply with regulatory requirements, impacting market perceptions and stock liquidity. The reduction below 50% could influence Alkem’s governance and investor relations dynamics.
The sale took place amid a positive market environment, with the Sensex closing at 74,649.84 and the Nifty at 23,483.55 on the day of the transaction, according to thehindubusinessline.com. This block deal represents a substantial capital movement for Alkem Laboratories and sets a new benchmark for promoter shareholding in the company.